FDA Communication with States

Sign up for email alerts on Compounding

The Compounding Quality Act requires the Secretary to establish a mechanism to receive submissions from state boards of pharmacy concerning certain actions taken against compounding pharmacies or expressing concerns that a compounding pharmacy may be acting contrary to section 503A.

This section is to be implemented in consultation with the National Association of Boards of Pharmacy (NABP).

In addition, state boards of pharmacy must be notified when the Secretary receives certain state submissions or makes a determination that a compounding pharmacy is acting contrary to section 503A.

Additional Information

• Inter-governmental Working Meeting on Pharmacy Compounding, March 18-19, 2015
  • FDA Responses to Action Items from March 18-19, 2015 Inter-governmental Working Meeting on Pharmacy Compounding
• Inter-governmental Working Meeting on Pharmacy Compounding, March 20-21, 2014 
  • FDA Responses to Action Items From March 20-21, 2014 Inter-governmental Working Meeting on Pharmacy Compounding
• "Dear Colleague” Letter to States (PDF - 1.3MB)